B-
BiotechTV - News
Jefferies 2026: Nektar Therapeutics has Rezpeg moving full speed ahead in atopic dermatitis and alopecia (and beyond) - the Head of R&D shares learnings about its mechanism
0:00-11:17
Jonathan Zalevsky describes how learnings from the phase 2 AD trial have helped with the study design of three phase 3 studies - and the latest on alopecia. He emphasizes how the company seems to be seeing a deepening of responses from this Treg targeting mechanism over time.
Publisher
BiotechTV - News
Link
podcasters.spotify.com/pod/show/biotechtv4/episodes/Jefferies-2026-Nektar-Therapeutics-has-Rezpeg-moving-full-speed-ahead-in-atopic-dermatitis-and-alopecia-and-beyond---the-Head-of-RD-shares-learnings-about-its-mechanism-e3sfudv
Published
November 16, 2026
Duration
11 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
BiotechTV
B-
BiotechTV - News
@biotechtvnews
#nektartherapeutics #atopicdermatitis #shareslearnings #lifesciences
